A 3-month, Multicenter, Randomized, Open Label Study to Evaluate the Impact of Early Versus Delayed Introduction of Everolimus on Wound Healing in de Novo Kidney Transplant Recipients With a Follow-up Evaluation at 12 Month After Transplant (NEVERWOUND Study)

Trial Profile

A 3-month, Multicenter, Randomized, Open Label Study to Evaluate the Impact of Early Versus Delayed Introduction of Everolimus on Wound Healing in de Novo Kidney Transplant Recipients With a Follow-up Evaluation at 12 Month After Transplant (NEVERWOUND Study)

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jun 2017

At a glance

  • Drugs Everolimus (Primary) ; Mycophenolate sodium (Primary)
  • Indications Renal transplant rejection
  • Focus Registrational; Therapeutic Use
  • Acronyms NEVERWOUND
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 20 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 13 Jan 2015 According to the ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
    • 03 Jun 2014 Planned number of patients changed from 214 to 396, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top